Zymeworks squares up with Her­ceptin af­ter HER2 bis­pe­cif­ic aces mid-stage test in esophageal can­cer

Roche’s Her­ceptin has long stood as stan­dard of care across mul­ti­ple ad­vanced can­cers, but a suite of next-gen play­ers are look­ing to beat the ag­ing gi­ant at its own game. In HER2-ex­press­ing esophageal can­cer, BeiGene part­ner Zymeworks thinks its bis­pe­cif­ic an­ti­body could have the juice to get it done.

Zymeworks’ bis­pe­cif­ic an­ti­body zanidatam­ab, com­bined with one of two chemother­a­py reg­i­mens, post­ed an over­all re­sponse rate of 75% in pa­tients with ad­vanced gas­troe­sophageal ade­no­car­ci­no­ma (GEA) who had not pre­vi­ous­ly re­ceived a HER2-tar­get­ed can­cer ther­a­py, the Van­cou­ver-based biotech said Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER